Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

After Bad Data Comes Layoffs – Will The Next Job Cuts Be At Anthera?

Mar 16 2018

• By Mandy Jackson

Desperate businessmen

Related Content

Pfizer Exits Early Neuroscience, But M&A Could Allow Later Re-Entry

Jan 09 2018

J.P. Morgan Notebook Day 1: Tax Reform At Last, Allergan's Job Cuts, Teva Turnaround, Biogen's Cash, And Getting FDA-Friendly

Jan 09 2018

Anthera jumps 25% on blisibimod update, new endpoint

Feb 11 2015

Vernalis Seeks Buyers, CEO To Step Down, As US Commercial Strategy Disappoints

Mar 15 2018

More US Positions Go As Daiichi Sankyo Refocuses

Mar 06 2018

Finance Watch: Another Mega-Round As Moderna Bucks Biopharma's IPO Trend

Feb 05 2018

Eight Clinical Trial Read-Outs To Look Out For In Early 2018

Feb 07 2018

Hung Out As Axovant Rebuilds Its Pipeline, Expands Focus Beyond Dementia

Feb 13 2018

Jobs Go At Shield Therapeutics As Failed Study Fallout Hits

Feb 23 2018

Achillion Keeps Focus On Complement Factor D Inhibitors As J&J Exits HCV

Sep 12 2017

Related Companies

Anthera Pharmaceuticals, Inc.

Eli Lilly and Company

Amgen, Inc.

Achillion Pharmaceuticals, Inc.

Johnson & Johnson

Johnson & Johnson

Daiichi Sankyo Co., Ltd.

Shield Therapeutics plc

Sio Gene Therapies, Inc.

Fresh Tracks Therapeutics, Inc.

Pfizer Inc.

Allergan plc

Ligand Pharmaceuticals, Inc.

Additional Topics

Business Strategies Clinical Trials Commercial BioPharmaceutical

More from Strategy

More from Business

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window